Cureus | Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review | Article
NOAC Dose-Adjustment Recommendations in Renal Impairment and AF | Download Table
Xarelto® - Dosing Guide
Xarelto® rivaroxaban Prescriber Guide
Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist | touchCARDIO
Dosing & Treatment Information | XARELTO® (rivaroxaban) HCP
Xarelto Full Prescribing Information, Dosage & Side Effects | MIMS Philippines
Xarelto® (rivaroxaban) Prescriber Guide Version 5
Dosing - DVT & PE Initial Treatment | XARELTO® (rivaroxaban) HCP
Xa Inhibitors - Apixaban and Rivaroxaban Oral Xa ... | GrepMed
Direct Oral Anticoagulants - ppt video online download
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study | Scientific Reports
Safety Profile - NVAF | XARELTO® (rivaroxaban) HCP
CorConsult Rx - #Repost @ambcarerx ・・・ Oral Anticoagulants have many chronic indications, most commonly VTE treatment/prophylaxis, atrial fibrillation, and valvular heart disease. VTE & AF can both be treated with either warfarin
Xarelto® - Dosing Guide
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants | Journal of the American College of Cardiology
Xarelto® - Dosing Guide
Life on a Blood Thinner: Insights and Advice from an Anticoagulant Specialist - YouTube
Rivaroxaban (Xarelto) for Prevention of Thromboembolic Events | AAFP
Xarelto: Package Insert - Drugs.com
Cureus | Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh | Article
Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation | Journal of the American College of Cardiology
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Remedial dosing recommendation for delayed or missed rivaroxaban doses for patients with non-valvular atrial fibrillation based on Monte Carlo simulation | medRxiv
